1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,235 | 0,301 | 10.10. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 01.10. | AcouSort AB: AcouSort AB enters into strategic OEM supply agreement with Calyrex Biosystems Inc. and Marketing agreement with Intelmetis Inc. combined with a SEK 15m convertible note financing | 126 | GlobeNewswire (Europe) | AcouSort AB (publ) ("AcouSort" or the "Company") today announces that it has entered into an OEM supply and development agreement (the "OEM Supply Agreement") and a marketing consulting agreement (the... ► Artikel lesen | |
| 26.08. | AcouSort AB Q2 Loss Increases | 2 | RTTNews | ||
| ACOUSORT Aktie jetzt für 0€ handeln | |||||
| 26.08. | AcouSort AB: AcouSort AB - Interim Report for the period January - June 2026 | 151 | GlobeNewswire (Europe) | The "Company" or "AcouSort" refers to AcouSort AB (publ) with corporate registration number 556824-1037
April-June 2026 for the Group• Net sales amounted to TSEK 2,116 (1,551)• Result before tax amounted... ► Artikel lesen | |
| 27.05. | AcouSort AB: AcouSort AB - Interim Report for the period January - March 2026 | 186 | GlobeNewswire (Europe) | The "Company" or "AcouSort" refers to AcouSort AB (publ) with corporate registration number 556824-1037.
First quarter 2026 for the GroupNet sales amounted to TSEK 2,147 (1,595)Result before tax amounted... ► Artikel lesen | |
| 10.03. | AcouSort AB: AcouSort receives prepayment of royalties | 329 | GlobeNewswire (Europe) | AcouSort AB today announced the signing of an amendment to its license and distribution agreement with the leading blood-gas analyzer company, Werfen. Under the amendment, Werfen will prepay minimum... ► Artikel lesen | |
| 25.02. | AcouSort AB: Year end report for AcouSort AB 1 January - 31 December 2025 | 232 | GlobeNewswire (Europe) | The "Company" or "AcouSort" refers to AcouSort AB (publ) with corporate registration number 556824-1037.October - December 2025 for the GroupNet sales amounted to TSEK 2,459 (1,221)Result before tax... ► Artikel lesen | |
| 19.12.25 | AcouSort AB: AcouSort and MFX enter a collaboration to streamline future cell therapy manufacturing | 1.200 | GlobeNewswire (Europe) | AcouSort AB today announced it has entered a collaboration with MFX, a UK-based developer of next-generation scalable bioreactor platforms, to evaluate if AcouSort's technology can be paired with MFX's... ► Artikel lesen | |
| 15.12.25 | AcouSort AB: Stefan Blomsterberg elected new Chairman of the Board of AcouSort | 279 | GlobeNewswire (Europe) | AcouSort AB today announced that Stefan Blomsterberg has been appointed new Chairman of the Board, effective January 1, 2026.
Stefan Blomsterberg currently holds the position as CEO of CELLINK Bioprinting... ► Artikel lesen | |
| 26.11.25 | AcouSort AB: AcouSort AB - Interim Report for the period January - September 2025 | 258 | GlobeNewswire (Europe) | The "Company" or "AcouSort" refers to AcouSort AB (publ) with corporate registration number 556824-1037.
July - September 2025 for the GroupNet sales amounted to TSEK 1,248 (1,198)Result before tax... ► Artikel lesen | |
| 19.11.25 | AcouSort AB: AcouSort and Danish SeeQ Diagnostics sign technology evaluation agreement | 434 | GlobeNewswire (Europe) | AcouSort AB today announced it has signed a technology evaluation agreement with the Danish diagnostics company SeeQ Diagnostics concerning the evaluation of AcouSort's blood/plasma separation technology... ► Artikel lesen |
10 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NOVONESIS | 58,32 | -0,03 % | Novonesis (Novozymes A/S): Transactions under Novonesis' share buyback program | ||
| BIOCRYST PHARMACEUTICALS | 7,594 | 0,00 % | BioCryst Pharmaceuticals, Inc.: BioCryst Announces Formation of Scientific Advisory Board to Drive Rare Disease Pipeline Innovation and Growth | -Supports BioCryst's evolution toward a more disciplined R&D model centered on external innovation- RESEARCH TRIANGLE PARK, N.C., Oct. 05, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:... ► Artikel lesen | |
| SARTORIUS STEDIM BIOTECH | 213,00 | 0,00 % | 1 Zellbank, 2 Geschäftsmodelle: Warum Lonza, Sartorius Stedim Biotech und NurExone die Exosomenproduktion industrialisieren | ||
| ADMA BIOLOGICS | 10,360 | 0,00 % | Kehoe Law Firm, P.C.: ADMA Biologics (ADMA) Shareholder Alert: Kehoe Law Firm Investigates Potential Fiduciary Duty Breaches | Philadelphia, Pennsylvania--(Newsfile Corp. - August 5, 2026) - Kehoe Law Firm, P.C. is investigating whether certain officers and directors of ADMA Biologics, Inc. ("ADMA," "ADMA Biologics," or... ► Artikel lesen | |
| CRESCENT BIOPHARMA | 11,800 | +4,42 % | Crescent Biopharma, Inc.: Crescent Biopharma Announces FDA Clearance of IND Application for CR-002, a PD-L1-targeted Topoisomerase Inhibitor ADC, for the Treatment of Solid Tumors | Phase 1/2 APOLLO global clinical trial to evaluate CR-002 in multiple solid tumor types, including non-small cell lung cancer (NSCLC) and head and neck squamous cell carcinoma (HNSCC), on track to... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 259,86 | 0,00 % | Praxis Precision Medicine Q2 2026 Earnings Call Transcript | ||
| ERASCA | 16,030 | 0,00 % | Erasca, Inc.: Erasca Reports Second Quarter 2026 Business Updates and Financial Results | Updated ERAS-0015 data in U.S. trial highlighted compelling monotherapy efficacy in 2L+ KRAS G12X PDAC and continued favorable tolerability, as well as further advancement of panitumumab CRC combination... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 17,590 | 0,00 % | Summit Therapeutics Secures $2B Strategic Investment From AstraZeneca | LONDON (dpa-AFX) - Summit Therapeutics Inc. (SMMT) on Monday announced the closing of AstraZeneca's (AZN) $2 billion strategic equity investment, which will support accelerated development of... ► Artikel lesen | |
| QIAGEN | 40,190 | +1,55 % | Pharma-Aktien starten durch: Merck, Qiagen und Bayer im Höhenflug - KI-Boom und US-Megadeal befeuern Branche | Die Aktien von Pharma- und Biotech-Unternehmen erleben am Dienstag einen starken Aufwärtstrend, angeführt von Merck KGaA. Investoren setzen auf Übernahmespekulationen und den KI-getriebenen Innovationsschub... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 4,360 | 0,00 % | 90% der Wirkstoffkandidaten scheitern: Wie Nvidia, Bristol Myers Squibb, Recursion und NeuroThera das größte Pharmaproblem angreifen | ||
| KINIKSA PHARMACEUTICALS | 79,78 | 0,00 % | Kiniksa Pharmaceuticals International, Plc: Kiniksa Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Portfolio Execution | - ARCALYST (rilonacept) Q2 2026 net product revenue of $243.6 million, representing ~55% year-over-year growth -- ARCALYST 2026 expected net product revenue increased to $980 - $995 million -- KPL-387... ► Artikel lesen | |
| MODERNA | 200,50 | -0,17 % | Moderna-Aktie: Steht der Ausbruch bevor? | Die Moderna-Aktie setzt ihre spektakuläre Erholung fort und notiert bei 190,01 US$. Damit hat der Kurs der Moderna-Aktie eine mehrjährige Widerstandszone überwunden. Der Ausbruch eröffnet technisch... ► Artikel lesen | |
| NURIX THERAPEUTICS | 22,350 | 0,00 % | Nurix Therapeutics, Inc.: Nurix Therapeutics Announces First Patient Enrolled in Phase 1b/2 Combination Study of Bexobrutideg in Chronic Lymphocytic Leukemia | First patient enrolled in cohort combining bexobrutideg with venetoclax Initial cohort to focus on relapsed/refractory CLL, with potential expansion to first-line CLL Strategy includes evaluation... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 112,45 | 0,00 % | Kymera Therapeutics: Raymond James startet Coverage mit "Outperform"-Rating | ||
| TANGO THERAPEUTICS | 23,820 | 0,00 % | Tango Therapeutics, Inc.: Tango Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights | Company continues to prepare for late-stage clinical advancement of vopimetostat in combination with daraxonrasib for pancreatic cancer following positive Phase 1/2 data Phase 1/2 data from combination... ► Artikel lesen |
ACOUSORT AB gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 0,247 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ACOUSORT AB finden Sie auf Wallstreet Online.